Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

1.

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.

Johnston SS, Turpcu A, Shi N, Fowler R, Chu BC, Alexander K.

Semin Arthritis Rheum. 2013 Aug;43(1):39-47. doi: 10.1016/j.semarthrit.2012.12.024. Epub 2013 Feb 27.

PMID:
23453683
[PubMed - indexed for MEDLINE]
2.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
[PubMed - indexed for MEDLINE]
3.

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2013 Jun;72(6):895-900. doi: 10.1136/annrheumdis-2012-201338. Epub 2012 Aug 11.

PMID:
22887849
[PubMed - indexed for MEDLINE]
4.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

PMID:
21439251
[PubMed - indexed for MEDLINE]
Free Article
5.

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.

Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, Spettell C, McMahan RM, Fernandes J, Winthrop K, Delzell E.

Ann Rheum Dis. 2011 Aug;70(8):1401-6. doi: 10.1136/ard.2010.146365. Epub 2011 May 17.

PMID:
21586439
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis.

Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell E, Saag KG, Safford MM, DuVall S, Alexander K, Napalkov P, Winthrop KL, Burton MJ, Kamauu A, Baddley JW.

Arthritis Care Res (Hoboken). 2014 Jul;66(7):990-7. doi: 10.1002/acr.22281.

PMID:
24470378
[PubMed - in process]
7.

TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis.

Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, Eisen SA.

Medicine (Baltimore). 2011 Mar;90(2):139-45. doi: 10.1097/MD.0b013e318211106a.

PMID:
21358439
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2007 Jan;56(1):13-20.

PMID:
17195186
[PubMed - indexed for MEDLINE]
Free Article
9.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
10.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Salliot C, Dougados M, Gossec L.

Ann Rheum Dis. 2009 Jan;68(1):25-32. doi: 10.1136/ard.2007.083188. Epub 2008 Jan 18. Review.

PMID:
18203761
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8.

PMID:
22886712
[PubMed - indexed for MEDLINE]
12.

Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study.

Ogale S, Hitraya E, Henk HJ.

BMC Musculoskelet Disord. 2011 Sep 19;12:204. doi: 10.1186/1471-2474-12-204.

PMID:
21929807
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. Review.

PMID:
19821440
[PubMed - indexed for MEDLINE]
14.

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.

Simon TA, Askling J, Lacaille D, Franklin J, Wolfe F, Covucci A, Suissa S, Hochberg MC; Abatacept Epidemiology Study Group.

Arthritis Res Ther. 2010;12(2):R67. doi: 10.1186/ar2984. Epub 2010 Apr 14.

PMID:
20398273
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians.

Arthritis Rheum. 2009 May 15;61(5):560-8. doi: 10.1002/art.24463.

PMID:
19405000
[PubMed - indexed for MEDLINE]
Free Article
16.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
[PubMed - indexed for MEDLINE]
17.

Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.

Bonafede MM, Gandra SR, Fox KM, Wilson KL.

J Med Econ. 2012;15(4):635-43. doi: 10.3111/13696998.2012.667028. Epub 2012 Mar 1.

PMID:
22332705
[PubMed - indexed for MEDLINE]
18.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099.

PMID:
23462785
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.

Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1480-9. doi: 10.1002/acr.21805.

PMID:
22833479
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.

Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR.

Ann Rheum Dis. 2014 Mar 7. doi: 10.1136/annrheumdis-2013-204011. [Epub ahead of print]

PMID:
24608404
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk